LATE
The latest sourced reporting on LATE from Dementias Today: dated, and plain about what the evidence does and does not show.
On one morning in 1947, 70,805 Scottish schoolchildren sat the same test. Decades on, some of them donated their brains. In the fastest decliners the myelin was thicker, the fibres were thinner, and the cells that lay down the insulation look like participants in the damage.
An unselected community brain collection, nearly 15,000 slides stained for tau, and seven cases. This is the counterweight to the athlete series, and it comes with hard limits of its own.
In 77 ADNI brain donors with confirmed Alzheimer's changes, Lewy body pathology tracked faster decline across four cognitive domains, while TDP-43 (LATE) change tracked slower loss of naming. Neither shifted neuropsychiatric symptoms.
An autopsy series of 148 frontotemporal cases and 42 with LATE-NC found the two could be told apart on full neuropathology, but not on the single frontal slide most brain banks rely on.
In a retrospective analysis of the ADNI research cohort, amyloid-positive patients in the lowest quartile of hippocampal volume were far more likely to show TDP-43 changes at autopsy, and declined faster; the authors say the cut-off could enrich trials, but it is not a test for LATE.
A retrospective study of 469 patients at the Geneva Memory Center reports that 36 people classified as probable LATE held steady on the MMSE over 30 months, while the Alzheimer and mixed groups declined. The authors say the classification has not been confirmed at autopsy.
A retrospective analysis of 944 brain FDG PET scans in the Journal of Nuclear Medicine used metabolic templates derived from six autopsy-confirmed LATE brains and 32 Alzheimer's brains, and found the two patterns most often sitting together rather than apart.
A retrospective study in Neurology applied the 2025 clinical criteria for limbic-predominant age-related TDP-43 encephalopathy to a Dutch tertiary memory clinic cohort, and found 8.2 percent were captured. Those groups differed from Alzheimer's disease in mortality and rate of decline, but nobody in the study had pathology confirmed.
An autopsy proteomics study of 90 hippocampi reports that a panel of eight mis-spliced transcripts tracks loss of TDP-43 function better than the protein clumps pathologists count, and that high scores go with lower levels of STMN2, ELAVL3, KALRN and two kinesins.
An unreviewed study of 90 people found cerebrospinal fluid TDP-43 separated four diagnostic groups, with probable LATE above both ALS and Alzheimer's disease. Nine LATE cases, no autopsy confirmation.